Market Access News | pharmaphorum

News

'Landmark' deal reached on UK voluntary rebate scheme

After months of wrangling, an agreement has finally been reached on a successor to the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), the system of reve

News

After FDA no, Almirall’s eczema drug gets EU okay

The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in

News

FDA’s Janet Woodcock will step down early next year

Janet Woodcock will bring a career at the FDA spanning almost four decades to a close next year, retiring from her current role as principal deputy commissioner of the reg

News

AZ first to AKT finish line, but FDA clears narrow label

AstraZeneca has claimed FDA approval for its first-in-class pan-AKT inhibitor capivasertib, getting a green light for the drug as a treatment for breast cancer, but with a

News

BMS gets US approval for ROS1 lung cancer drug Augtyro

Bristol-Myers Squibb has secured FDA approval for Augtyro, a lung cancer therapy it acquired as part of its $4.1 billion takeover of Turning Point Therapeutics last year t

News

UK first to approve Vertex, CRISPR drug for blood disorders

The first-ever CRISPR-based gene-editing therapy has been approved for marketing in the UK for inherited blood disorders sickle cell disease (SCD) and transfusion-dependen

'Landmark' deal reached on UK voluntary rebate scheme

After FDA no, Almirall’s eczema drug gets EU okay

FDA’s Janet Woodcock will step down early next year

AZ first to AKT finish line, but FDA clears narrow label

BMS gets US approval for ROS1 lung cancer drug Augtyro

UK first to approve Vertex, CRISPR drug for blood disorders

Andy Plump to step down as Takeda's R&D chief

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks